Navigation Links
Barr Announces Agreements on Nasacort(R) AQ, Allegra(R) D-12 and Allegra(R) Patent Challenges
Date:11/18/2008

- Settlement and License Agreement for Generic Versions of Nasacort(R) AQ

- Settlement and License Agreement with Aventis and Albany Molecular Research, Inc. for Generic Versions of Allegra(R) D-12

- Settlement Agreement with Aventis and Albany Molecular Research, Inc. Related to Generic Versions of Allegra(R) Tablets

MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ --Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort(R) AQ (triamcinolone acetonide) nasal spray, Allegra(R) D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra(R) (fexofenadine) 30mg, 60mg and 180mg tablets. As part of the settlements, the parties have agreed to dismiss the underlying U.S. litigation related to the three patent challenge cases.

"We are very pleased to have reached these three separate settlements, bringing to a close the outstanding patent challenges in a manner that results in the date certain launch of a generic version of Nasacort(R) AQ years prior to the expiration of the applicable patents, and the launch of a generic version of Allegra(R) D-12 in November of 2009," said Bruce L. Downey, Barr's Chairman and CEO. "The agreement related to Allegra(R) resolves any ongoing uncertainty about the possible impact of ongoing litigation for Barr and Teva related to the launch of generic versions of Allegra(R) 30mg, 60mg and 180mg tablets in September 2005. We believe that these agreements represent a pro-consumer resolution to this ongoing litigation."

The individual agreements are subject to review by the Federal Trade Commission (FTC) and state Attorneys General under
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Acumen Fund Announces New Investments In Pakistan To Build Scalable Business That Serve The Poor
2. QC Sciences™ Announces Innovative Solution to Reduce Laboratory Costs : The NuView System™ For Non-Gynecologic Cytology Affords Substantial Savings
3. Capella University Announces $50,000 in Scholarships to Graduate Students in Mental Health Services : Ten students are awarded scholarships at online university
4. Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations
5. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
6. Pregis Announces Third Quarter 2008 Financial Results
7. eDiets.com(R) Announces Q3 2008 Results
8. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
9. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
10. Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
11. In a Down Economy, Womens Health Company Announces Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 An ... a problem which could prove critical to organizations that ... testing, a critical aspect of data security, is worsening ... industry data security report, every major category out of ... and penetration testing. “With all the craziness that has ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:3/28/2015)... Purity Products®, a leading direct to ... of their revolutionary new weight loss product, MuffinStop™. ... placebo-controlled clinical studies to be effective in reducing ... is a combination of two traditionally used botanical ... to create one of the most innovative weight ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
... Researchers from the University of Pennsylvania School of Medicine ... determines the development of many cell types, and is ... for the maintenance of stem cells. The findings appear ... inhibitors of Notch may not affect bone marrow stem ...
... 1995, Tapped to Steer the World,s Largest Organization ... WHITE PLAINS, N.Y., April 10 The Leukemia & ... chief executive,officer, with the task of leading the world,s ... strives to find cures and,prolong and enhance the lives ...
... survived exposure, study reports, , , THURSDAY, April 10 (HealthDay ... anthrax vaccine that provides protection against the potentially deadly ... and combining two of anthrax,s lethal toxins, the researchers ... be more effective than vaccines that contain just one ...
... - 7,000 deaths ... significantly reduces pharmacy error risk, - Half of consumers choose their ... ... April 10 One-third of America,s 225,million prescription-takers now report experiencing ...
... N.J., April 10 Hooper Holmes,(Amex: HH ) today ... Executive Officer and that Benjamin A. Currier will continue as,Chairman ... a member of the,Board since May 30, 2007, had been ... basis on February 6, 2008., John W. Remshard, who ...
... state,s elderly, disabled, and ... ... cut hundreds of millions of dollars from Medicaid,programs for the elderly, disabled ... the leaders of Florida,s safety net,hospitals warned today., Besides jeopardizing the ...
Cached Medicine News:Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:The Leukemia & Lymphoma Society Announces Appointment of New President and CEO 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 3Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 3Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 2Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 3Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 2Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 3
(Date:3/27/2015)... 27, 2015 Across the global healthcare landscape, ... in clinical development, market education, and regulatory compliance. As ... Affairs function is expected to increase in prominence and ... According to research by benchmarking firm, Best Practices, ... dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... March 27, 2015 Object recognition technology has ... impaired and elderly. The VelaSense ® ... lead more independent, productive and fulfilling lives. VelaSense ® ... allow users to identify objects from a one million ... create customized object databases for personal use. ...
(Date:3/27/2015)... Ga. , March 27, 2015  Holographic Optical ... in the field of holographic medical imaging, is entering ... its Kickstarter campaign. Launching on April 20 th , ... and Voxbox Pro. The 8-inch and 22-inch displays will ... home for the first time. In addition to the ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg, 10 mg, 15 mg, and 20 mg. This product ... ® , which is indicated for the treatment of schizophrenia ...
... Young Innovations, Inc. (NASDAQ: YDNT ) today announced sales ... Sales for the first quarter of 2012 were ... the first quarter of 2011. Income from operations increased 5.3% to ... in the first quarter of 2011. Net income increased 5.6% to ...
Cached Medicine Technology:Mylan Launches Generic Version of Zyprexa® Tablets 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4
RIA kit for the quantitative determination of autoantibodies to IA-2 in serum...
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum...
Inquire...
Inquire...
Medicine Products: